Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

This Clinical-Research Stock Is Flying Under the Radar: Could It Be Ready for Its Next Big Move?

This clinical-research stock,ICONplc (NASDAQ:ICLR), is one of the world's largest contract research organizations, providing outsourced clinical-development and commercialization services to pharmaceutical, biotechnology, and medical-device companies. Shares closed at $164.85 at last closing, up 0.78%.

Nitish Kishor | 08 September 2026

HCA Healthcare (NYSE:HCA) Stock: Is It Quietly Coiling for a Breakout?

HCA Healthcare (NYSE:HCA) is one of the largest healthcare providers in the United States, operating a large network of hospitals and related facilities, including surgery centers, emergency and urgent-care sites, and other services. Shares closed at $405.00 at last closing, down 1.03%.

Nitish Kishor | 08 September 2026

Cooper Companies (NASDAQ:COO) Stock Slips Ahead of Earnings as Broader Market Pulls Back on Jobs Report

Cooper Companies (NASDAQ:COO) closed at $69.59 at last closing, down 1.49%, slipping ahead of its fiscal third-quarter 2026 earnings report due September 9, with Wall Street looking for EPS of roughly $1.11 on revenue near $1.10 billion, driven by CooperVision's premium lens and MyDAY …

Nitish Kishor | 08 September 2026

GE HealthCare (NASDAQ:GEHC) Stock: Why It Deserves a Fresh Look

GE HealthCare Technologies (NASDAQ:GEHC) is a leading medical-technology company focused on imaging, ultrasound, patient-care solutions, and pharmaceutical diagnostics, providing equipment, software, and services to hospitals and healthcare providers worldwide. Shares closed at $68.86 at last closing, down 1.23%.

Nitish Kishor | 08 September 2026

Abeona Therapeutics (NASDAQ:ABEO) Stock: What Should Investors Watch Next?

Abeona Therapeutics (NASDAQ:ABEO) is a commercial-stage biopharmaceutical company that has launched a gene therapy, marketed as Zevaskyn, for a serious rare genetic skin disease known as recessive dystrophic epidermolysis bullosa. Shares closed at $6.00 at last closing, up 1.18%.

Nitish Kishor | 08 September 2026

Solvonis Therapeutics Flatlines for the Day: Is a Bigger Move Brewing in SVNS?

Solvonis Therapeutics (LSE:SVNS), the AIM-quoted clinical-stage biopharmaceutical company, ended the latest session unchanged, a flat close that in a development-stage drug developer is entirely unremarkable. There was no fresh regulatory announcement on the day, and for a pre-revenue company whose value hinges on the …

Ankur Sharma | 08 September 2026

Penny Stock Neuronetics (NASDAQ:STIM) Stock Jumps: Is a Bigger Move Coming?

Penny stock Neuronetics (NASDAQ:STIM) is a commercial-stage medical-technology company whose NeuroStar system delivers transcranial magnetic stimulation for major depression, and following its 2024Mergerwith Greenbrook TMS it also operates a national network of TMS treatment centers. Shares closed at $2.88 at last closing, up 5.88%.

Nitish Kishor | 08 September 2026

Penny Stock SINTX Technologies (NASDAQ:SINT) Stock Jumps: Can the Rally Build From Here?

Penny stock SINTX Technologies (NASDAQ:SINT) is a small materials and medical-technology company focused on silicon-nitride ceramics and related biomaterials, which have applications in medical implants, such as spinal devices, and in antipathogenic and industrial uses. Shares closed at $1.63 at last closing, up 5.84%.

Nitish Kishor | 08 September 2026

Penny Stock Sensus Healthcare (NASDAQ:SRTS) Stock Slides: Opportunity or More Risk?

Penny stock Sensus Healthcare (NASDAQ:SRTS) is a medical-device company that makes superficial radiation therapy systems used to treat non-melanoma skin cancers and keloids, selling and placing its devices with physicians and clinics. Shares closed at $3.19 at last closing, down 2.15%.

Nitish Kishor | 08 September 2026

Neumora Therapeutics (NASDAQ:NMRA) Stock Slides: What's Left After Its Lead Drug's Phase 3 Failure?

Penny stock Neumora Therapeutics (NASDAQ:NMRA) is a clinical-stage biotechnology company focused on neuropsychiatric and neurodegenerative diseases. Shares closed at $1.31 at last closing, down 2.96%. Its lead program, navacaprant for major depressive disorder, failed its Phase 3 trials in June 2026 and was discontinued, …

Nitish Kishor | 08 September 2026
Support

Hi! How can we help you today?

Loading…